Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Board Declares Dividend, Approves Friel as CEO

NEW YORK (GenomeWeb News) — PerkinElmer said yesterday that its board of directors has declared a quarterly dividend and, as expected, has elected President and COO Robert Friel to the post of CEO.
 
The company said the quarterly dividend of $.07 per share of common stock is payable on May 9 to all shareholders of record by the close of business on April 18.
 
In a move consistent with the company’s 2007 leadership succession plan, PerkinElmer also announced that Friel will become its new CEO on Feb. 1. Friel, who joined the company as chief financial officer in 1999, became vice chairman and president of the firm’s life and analytical sciences business in 2006. Last year, he was promoted to president and chief operating officer. He also will retain the title of president after assuming the role of CEO.
 
“Rob has a long track record of results in a wide variety of challenging roles and knows the company extremely well,” Gregory Summe, executive chairman of PerkinElmer’s board, said in a statement. “The board of directors and I believe that Rob is the right leader to drive PerkinElmer’s future growth and expansion, and look forward to his continued success.”

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.